Knight Therapeutics (GUD) Scheduled to Post Earnings on Thursday

Knight Therapeutics (TSE:GUD) is scheduled to announce its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of C$0.03 per share for the quarter.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings data on Thursday, May 9th. The company reported C($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.06). The firm had revenue of C$86.60 million during the quarter, compared to analyst estimates of C$80.27 million. Knight Therapeutics had a negative net margin of 5.25% and a negative return on equity of 2.21%.

Knight Therapeutics Trading Down 0.2 %

Shares of Knight Therapeutics stock traded down C$0.01 on Tuesday, reaching C$5.54. 56,193 shares of the company’s stock were exchanged, compared to its average volume of 65,019. The company has a debt-to-equity ratio of 9.20, a quick ratio of 1.79 and a current ratio of 3.34. The firm’s 50-day moving average is C$5.69 and its two-hundred day moving average is C$5.64. Knight Therapeutics has a 52 week low of C$4.35 and a 52 week high of C$6.22. The company has a market capitalization of C$561.65 million, a P/E ratio of -34.69, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.46.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lifted their target price on Knight Therapeutics from C$5.40 to C$5.75 in a report on Friday, May 10th.

Insider Buying and Selling

In other Knight Therapeutics news, Senior Officer Amal Khouri sold 20,000 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of C$5.80, for a total value of C$116,022.00. In related news, Director Jonathan Ross Goodman acquired 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average price of C$5.80 per share, with a total value of C$29,000.00. Also, Senior Officer Amal Khouri sold 20,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total value of C$116,022.00. Insiders have sold a total of 75,000 shares of company stock valued at $437,533 over the last ninety days. Company insiders own 46.36% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.